✦ LIBER ✦

Reply: Rebound psychosis in Parkinson's disease

✍ Scribed by Hubert H. Fernandez; Michael S. Okun

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 35 KB
Volume: 20
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.20431

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The original letter to which this reply refers was published in Movement DisordersMov Disord (2005) 20 (4) 515.

📜 SIMILAR VOLUMES

The neurochemical mechanism of rebound p

The neurochemical mechanism of rebound psychosis in Parkinson's disease

✍ Spiridon Papapetropoulos; Deborah C. Mash 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 35 KB 👁 1 views

## Abstract A reply to this letter has been published in __Movement__ DisordersMov Disord (2005) 20 (4) 515.

Rebound psychosis: Effect of discontinua

Rebound psychosis: Effect of discontinuation of antipsychotics in Parkinson's disease

✍ Hubert H. Fernandez; Martha E. Trieschmann; Michael S. Okun 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 44 KB

## Abstract To determine whether psychiatrically stable patients with a history of drug‐induced psychosis could be successfully weaned off their antipsychotic drug, we offered consecutive Parkinson disease (PD) patients on quetiapine or clozapine, who were free of any on‐going psychosis, to be slow

Psychosis in Parkinson's disease

✍ Werner Poewe 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

Psychosis is a disabling nonmotor complication of Parkinson's disease (PD). Visual hallucinations are the most common clinical manifestation and have been observed in up to 40% of patients with advanced disease in hospital-based series. Age, cognitive dysfunction, depression, as well as severity and

Clozapine for psychosis in Parkinson's d

Clozapine for psychosis in Parkinson's disease

✍ Dr. Ronald F. Pfeiffer; Jasbir Kang; Benjamin Graber; Ruth Hofman; James Wilson 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 321 KB 👁 1 views

## Abstract The clinical efficacy of clozapine, an atypical antipsychotic, in treating levodopa‐induced hallucinations was investigated in five patients with Parkinson's disease under open label conditions. Two patients could not tolerate clozapine, even in doses as low as 12.5–25 mg daily, because

Reply: Intravenous glutathione in Parkin

Reply: Intravenous glutathione in Parkinson's disease

✍ Robert A. Hauser; Kelly E. Lyons 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 273 KB 👁 1 views

We appreciate the careful reading of our manuscript by Okun and colleagues. 1 However, their letter contains a number of inaccuracies that require correction. We clearly state

Reply: Neuropsychiatric symptoms in Park

Reply: Neuropsychiatric symptoms in Parkinson's disease

✍ D. Aarsland; L. Marsh; A. Schrag 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 51 KB